Short Interest in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Decreases By 13.7%

Neumora Therapeutics, Inc. (NASDAQ:NMRA) saw a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 5,216,610 shares, a decrease of 13.7% from the February 12th total of 6,045,735 shares. Currently, 4.3% of the company’s shares are sold short. Based on an average daily trading volume, of 870,409 shares, the short-interest ratio is currently 6.0 days. Based on an average daily trading volume, of 870,409 shares, the short-interest ratio is currently 6.0 days. Currently, 4.3% of the company’s shares are sold short.

Insider Buying and Selling

In other Neumora Therapeutics news, insider Paul L. Berns sold 9,819 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total transaction of $34,464.69. Following the completion of the sale, the insider owned 7,395,185 shares of the company’s stock, valued at approximately $25,957,099.35. This represents a 0.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 23,387 shares of company stock valued at $82,647 in the last quarter. Corporate insiders own 26.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Henson Edgewater Management LLC purchased a new position in Neumora Therapeutics in the 4th quarter worth approximately $292,000. Virtu Financial LLC boosted its stake in Neumora Therapeutics by 465.7% in the fourth quarter. Virtu Financial LLC now owns 97,408 shares of the company’s stock worth $174,000 after buying an additional 80,189 shares in the last quarter. Invesco Ltd. raised its stake in shares of Neumora Therapeutics by 23.8% during the fourth quarter. Invesco Ltd. now owns 227,594 shares of the company’s stock worth $407,000 after acquiring an additional 43,795 shares in the last quarter. XTX Topco Ltd purchased a new stake in Neumora Therapeutics during the fourth quarter valued at about $204,000. Finally, Ikarian Capital LLC grew its stake in shares of Neumora Therapeutics by 10,128.9% during the fourth quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after buying an additional 1,265,910 shares during the last quarter. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Price Performance

Shares of NMRA stock traded down $0.10 during trading hours on Wednesday, reaching $2.74. The stock had a trading volume of 205,283 shares, compared to its average volume of 1,762,747. The stock’s fifty day simple moving average is $2.69 and its 200 day simple moving average is $2.27. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $456.99 million, a PE ratio of -1.86 and a beta of 2.49. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $3.65.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on NMRA shares. William Blair raised shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $4.00 to $7.00 in a research note on Monday, December 1st. Mizuho set a $6.00 target price on shares of Neumora Therapeutics in a research note on Monday, January 5th. Leerink Partners began coverage on shares of Neumora Therapeutics in a research report on Monday, January 12th. They set an “outperform” rating and a $8.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $6.71.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.